The live webcast can be accessed by visiting the Investors section of the Companys website at investors.ocutx.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (844) 464-3934 (U.S.) or (765) 507-2620 (International) to listen to the conference call. The conference ID number for the live call will be 58560807. One Category Is Usually Called routine Care, wellness Visits Or preventative Care See Definition Below . | Alexander Reynolds TownAn archive of the webcast will be available until August 23, 2016 on the Companys website. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. ( OCUL ) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. no dataOcular Therapeutix’s lead product candidate, DEXTENZA (dexamethasone insert), is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and in Phase 2 clinical development for dry eye disease. A third Phase 3 clinical trial is being conducted for post-surgical ocular inflammation and pain.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/ocular-therapeutix-report-second-quarter-200500340.html